Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Fig. 1

A total of 105 patients met the inclusion criteria and were randomized. Six patients in the empagliflozin group and three patients in the placebo group were excluded because of consent withdrawal before medication begun. Therefore, 96 patients were included in the full analysis set (46 in the empagliflozin group and 50 in the placebo group)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840